Distribution Appropriateness Committee

In order to ensure sustainable distribution of ethical drugs in the future, the committee investigates, analyzes, and examines matters related to commercial distribution and logistics, focusing on quality assurance, realization of stable supply, and sound market formation.

To investigate and analyze the impact of changes in laws, systems, and the environment related to healthcare on the promotional activities of pharmaceutical companies, and to study and make recommendations on what the industry should be and the issues that need to be addressed.

To grasp trends in the medical care system, centering on the reimbursement system and the drug price standard system, and to study and evaluate their impact on the distribution of ethical pharmaceuticals.

Grasp the status of studies toward the expansion of utilization in medical care and distribution, including auditing, recording, data linkage, and efficiency improvement using specific code utilization methods, and analyze and build opinions from the manufacturer's perspective.

To take necessary actions such as continuous monitoring and investigation of the overall trend of ethical drug distribution and organizing issues to be addressed in the ethical drug transaction data exchange system, in order to contribute to further rationalization and standardization of ethical drug transactions.

Based on the discussions of the "Expert Panel Report" and the "Revised Guidelines for Improvement of Distribution", the actual conditions of the distribution system will be identified. Furthermore, the external environment, changes in healthcare-related systems, and technological advancements will be investigated and analyzed, and the transparency, fairness, stable supply, efficiency, and sustainability of drug distribution will be examined.

Concerning the promotional activities of pharmaceutical companies, surveys and analyses will be conducted on the impact and changes resulting from the progress of digitalization, the implementation and operation of healthcare-related systems and guidelines, and the impact of changes in the external environment such as the promotion of formulary dissemination and reforms in the way doctors work. Based on these surveys and analyses, the committee will study and make proposals on issues and measures for the future development of promotion activities that should be carried out by pharmaceutical companies, in cooperation with related organizations and committees within the Pharmaceutical Manufacturers Association of Japan (PMAJ).

We will conduct surveys and research, paying attention to discussions at the Central Social Insurance Medical Council (Chuikyo) and other councils, and keeping abreast of trends in mid-year revisions, drug price reforms, and the promotion of digital transformation (DX) in healthcare, to examine and evaluate the impact of these system reforms on the medical field and prescription drug distribution. and evaluate the impact of these system reforms on the medical field and ethical drug distribution.

(iii) Ensure medical safety through advanced utilization of codes for specific use, expand traceability, improve operational efficiency, understand trends toward record maintenance, etc., and analyze trends in unutilized facilities. In addition, we will also focus on the awareness of users of the issues they face in promoting the utilization of the system and the environmental improvement by administrative agencies, and organize the issues from the manufacturers' perspective and study the necessary measures to be taken.

To further streamline and standardize the ethical drug transaction data exchange system, we will negotiate and coordinate with related organizations and revise industry standard manuals. In addition, we will keep abreast of current efforts in distribution as a whole and in information technology, and from the standpoint of an information system specialist, continue to study and research the direction of the industry and the necessary responses to regulations, etc. Regarding the new industry standard EDI unified data format that went into effect in November 2024 and the JD-NET 8th system that began operation, we will continue to study and research the new EDI unified data format that went into effect in November 2024, and the JD-NET 8th system that began operation, Promote the new EDI unified data format, which came into effect in November 2024, and the JD-NET 8th system, which began operating, in cooperation with related organizations, including the Japan Pharmaceutical Wholesalers Association (JPWA), so that each company's system will be compatible by November 2027, when the new and old formats are in parallel operation.